FibroScan approved indications

The intended use for the FibroScan family of products.

The FibroScan intended use

The intended use/indications for use for the FibroScan are as follows:

The FibroScan Family of Products (Models: 502 Touch, 530 Compact, and 430 Mini+) is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP™: Controlled Attenuation Parameter) in internal structures of the body.

FibroScan Family of Products (Models: 502 Touch, 530 Compact, and 430 Mini+) is indicated for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter).

The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.

Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.

Additionally, the FibroScan technology complies with all applicable rules governing the level of energy applied and absorbed to the human body, including mechanical indexes and heat dissipation.

Clinical practice guidelines

FibroScan, patented VCTE™ technology is the reference for the non-invasive assessment of liver disease in many internationally recognized treatment guidelines, across specific etiologies of Liver Disease.

Request to be contacted

Clinical practice guidelines

Etiology of Liver Disease
Downloads / More Information
New recommendations for evaluations of liver health in TD2M patients. ADA: Standards Of medical Care in Diabetes - 2019
Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases
AGA Guidelines
Institute Technical Review on the Role of Elastography in Chronic Liver Diseases
AGA Guidelines
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Recommendations for Testing, Managing and Treating Hepatitis C; When & In Whom to Initiate Antiviral Therapy, AASLD & IDSA Practice Guidelines
EASL Clinical Practice Guidelines: Noninvasive Tests for Evaluation of Liver Disease Severity and Prognosis; Journal of Hepatology 2015
Journal of Hepatology 2016 vol 64/1388-1402
WHO Guidelines for Screening, Care and Treatment of Persons with Hepatitis C Infection; ISBN 978 92 4 154875 5
Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection. 2015 WHO Algorithm of WHO recommendations of the Management of Persons with Chronic Hepatitis B infection (Page xxvi)
HCV & Co-infection
Management of HCV & HIV co-infection WHO 2012 HIV/AID treatment. Clinical Protocol for the WHO European Region Chapter 6
Diagnosis and Management of Chronic Hepatitis B in Children, Young People OR Adults
These references represent uses of FibroScan in published literature. Echosens does not intend to make any of the specific claims found in these articles. FibroScan is a tool to aid in the clinical management of liver disease, and is not intended for the treatment of any specific liver disease or condition.

Current media

December 9, 2020 in All, Blog

Echosens Featured in OncologyTube

Scott Howell, DO, MPH & TM, CPE, Advisor to Echosens, was featured in OncologyTube interview: “Underlying Nonalcoholic Fatty Liver Disease is a Significant Factor for Breast Cancer Recurrence After Curative…
Read More
November 19, 2020 in All, Blog

Comprehensive Economical Analysis Shows Screening Diabetic Patients for NAFLD is Cost Effective in the United States

The prevalence of non-alcoholic fatty liver disease (NAFLD) has reached epidemic levels. The most common liver disease, with a worldwide prevalence of 25%, NAFLD and its subtype, nonalcoholic steatohepatitis (NASH),…
Read More
November 17, 2020 in All, Press Releases

Echosens Presents Research at 2020 AASLD Liver Meeting

November 13, 2020 08:03 AM Eastern Standard Time Documentation for Payers on Cost Effectiveness of FibroScan Screening for Detecting, Monitoring Fatty Liver Disease WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering…
Read More

Contact a representative

In North America there are over 1200+ FibroScan systems in operation & we’re growing!

Speak to a Representative